Company: NIVFW
Filing Date: 2025-03-07
Form Type: F-1
Source: 0001213900-25-021404
Chunk: 109

Company: NewGenIvf Group Ltd
Filing Date: 2025-03-07
Form: F-1
Chunk 109
---
            |   |
| Net cash (used in)/provided            
 by operating activities                |     |                | (1,766,135 | ) |     |      |  1,710,901 |   |
| Net cash used in investing activities  |     |                |    (69,848 | ) |     |      |    (94,452 | ) |
| Net cash provided by/(used in)         
 financing activities                   |     |                |  1,881,493 |   |     |      | (1,633,781 | ) |
| Net increase/(decrease) in cash        
 and cash equivalents                   |     |                |     45,510 |   |     |      |    (17,332 | ) |
| Effect of foreign currency translation 
 on cash and cash equivalents           |     |                |    (18,962 | ) |     |      |     16,124 |   |
| Cash and cash equivalents, beginning   
 of year                                |     |                |     27,556 |   |     |      |     28,764 |   |
| Cash and cash equivalents, end         
 of year                                |     |                |     54,104 |   |     |      |     27,556 |   |

Operating activities Net cash used in operating activities was US$2,616,131 for the nine month period ended September 30, 2024. The difference between NewGenIvf’s net profit of US$832,640 for the nine month period ended September 30, 2024 and the net cash used in operating activities was primarily attributable to legal fee payable, accrued liabilities and other payables. Net cash used in operating activities was US$1,766,135 for the year ended December 31, 2023. The difference between NewGenIvf’s net profit of US$108,418 for the year ended December 31, 2023 and the net cash used in operating activities was primarily attributable to refund of payment from clients from the contract liabilities and the expenses spent on the legal and professional cost which was capitalized in the book of 2023. 78 Net cash provided by operating activities was US$1,710,901 for the year ended December 31, 2022. The difference between NewGenIvf’s net income of US$135,847 for the year ended December 31, 2022 and the net cash provided by operating activities was primarily attributable to